Fundraise

Annovis raises $21M to reach pivotal Alzheimer's readout

What's the deal? Annovis BioDealroom has a profile for this one. Try Dealroom → raised $21 million in a November stock offering to fund operations through a key Alzheimer's trial readout due in March 2027. The Malvern-based biotech closed the underwritten public offering November 6, with its board chairman contributing $5 million.

Why now? Cash reserves had fallen to $2.8 million as of September 30, down from $19.5 million at the end of 2025, as spending on clinical programs accelerated. Research and development expenses jumped to $15.8 million in the third quarter, up from $6.3 million a year earlier.

What's the endgame? The money supports DUET-AD, the company's Phase 3 trial of oral treatment buntanetap. The study has enrolled 862 patients with early Alzheimer's who tested positive for the blood biomarker pTau217.

The six-month analysis, assessing symptomatic effects, will follow a database lock on February 8 and deliver topline results in March 2027. Patients then continue treatment for a further 12 months to complete a separate 18-month assessment of potential disease-modifying effects.

What's next? Annovis is preparing a New Drug Application for the Food and Drug Administration and wants to complete a substantial portion before the March results land. In September, it partnered with Weave Bio to use artificial intelligence tools for regulatory documentation.

"The third quarter marked a shift in our focus from enrolling patients in DUET-AD to executing the trial and preparing for the first data readout and for filing a New Drug Application," said president and chief executive officer Maria Maccecchini.

The signal: With roughly $2.8 million in the bank against mounting losses, the raise buys Annovis just enough runway to reach its first major efficacy test — a binary moment that will determine whether buntanetap advances toward approval or not.

Read more: mychesco.com

Image credit: Generated with Gemini

More top stories